GATC highlighted in Stifel report, “AI in Biopharma”

Plus: Seeking Alpha article addresses clinical success rates for AI-generated drugs.

IRVINE, CA, May 14, 2024—Interest in AI-derived drugs and AI-expedited drug development processes are on the rise and making news. GATC Health is proud to be featured in the recent report, “AI in Biopharma,” released by our investment banking firm, Stifel. See page 123.
 
This report provides an in-depth look at the variety of prevalent investment theses for AI-focused drug discovery and development companies. Management feels that GATC Health addresses many of the more pressing issues covered in this report—a conviction that is shared by our bankers at Stifel.
 
We also invite you to read a recent article in Seeking Alpha, that takes a look at a new study regarding clinical success rates for AI-generated drug candidates. It details how companies like GATC Health are providing tremendous value to the pharma market, particularly in the early development stages. GATC Health believes that its drug candidates will out-perform competitors’ assets in the clinic, due to its AI platform’s proven ability to identify sensitivity and specificity for drug assets with a very high level of precision. The company has seven AI-generated drug candidates in its pipeline that have been validated by GATC’s proprietary in silico processes.
 
More from the article:  

AI-discovered molecules can have an 80%–90% success rate in Phase 1 clinical studies, a group of researchers from Boston Consulting Group said in a recent peer-reviewed article in the journal Drug Discovery Today.  

“This suggests that the 'coming wave' of AI in R&D, which is already well-documented in drug discovery, is now occurring at the clinical trial stage,” the analysts led by Madura Jayatunga wrote.  

The group based their findings on pipeline data from more than 100 AI-focused biotechs. Citing data from 2015, they said those biotechs, along with their pharma partners, have advanced 75 molecules into the clinic by 2023, out of which 67 are undergoing clinical trials.

With each of the top 20 pharma companies indicating interest in AI-led drug discovery, this number has increased at a compound annual growth rate of more than 60% over the past ten years.

About GATC Health

GATC Health Corp is a technology company revolutionizing disease prediction and drug discovery and development through its transformative AI platform and approach, which de-risks drug pipelines and accelerates new therapies to treat disease with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid disease prediction, novel target identification, and drug discovery and development. GATC envisions the future of medicine now, where health is protected, disease is reversed and every person’s unique biology is treated with precision.